<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04146259</url>
  </required_header>
  <id_info>
    <org_study_id>1387/08-12-2015</org_study_id>
    <nct_id>NCT04146259</nct_id>
  </id_info>
  <brief_title>Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism</brief_title>
  <official_title>Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate changes in sclerostin levels following acute post-thyroidectomy
      hypoparathyroidism
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Female patients with thyroid disorders, referred to the Department of Head and Neck Surgery,
      at Metaxa Anti-Cancer Hospital of Piraeus, for total thyroidectomy.

      Based on the development of biochemical hypocalcemia (cCa &lt; 8.4 mg/dl), subjects were divided
      into 2 groups: Group A: without postsurgical hypoparathyroidism that served as controls and
      group B: subjects, with acute postsurgical hypoparathyroidism.

      Blood collections were performed in the morning after an overnight fast, in at least 3
      different time points; preoperatively, 1st postoperative day and 7th postoperative day for
      the detrmination of sclerostin levels
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">August 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in circulating serum sclerostin levels (pmol/L) during the observation period</measure>
    <time_frame>7 days</time_frame>
    <description>change in circulating serum sclerostin levels (pmol/L)during the observation period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the between groups difference in % changes of circulating sclerostin</measure>
    <time_frame>7 days</time_frame>
    <description>the between groups difference in % changes of circulating sclerostin</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">109</enrollment>
  <condition>Hypoparathyroidism Postprocedural</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Post-surgical hypoparathyroidism</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcium carbonate and alphacalcidol</intervention_name>
    <description>treatment for hypocalcemia</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients with indication for total thyroidectomy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for total thyroidectomy

        Exclusion Criteria:

          -  parathyroid disorders, chronic kidney disease (eGFR&lt; 60 ml/min), treatment with
             antiosteoporosis drugs, rheumatic disease and history of long term (&gt;1 month) or
             current corticosteroid use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Symeon Tournis</name>
      <address>
        <city>Athens</city>
        <zip>14561</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Symeon tournis</investigator_full_name>
    <investigator_title>Senior Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Sclerostin</keyword>
  <keyword>Hypoparathyroidism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfacalcidol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

